Bayer and Broad Institute Extend Landmark Collaboration to Advance Cardiovascular Genomics and Precision Medicine In a bold continuation of a decade-long scientific alliance, Bayer and the Broad Institute of MIT and Harvard have announced a five-year extension of their ongoing…
Bristol Myers Squibb Unveils Compelling Late-Breaking Phase 3 Data Highlighting the Efficacy of Sotyktu (Deucravacitinib) in Treating Psoriatic Arthritis Bristol Myers Squibb has announced new late-breaking clinical data from the pivotal Phase 3 POETYK PsA-1 trial, reinforcing the potential of…
FDA Expands Approval of AbbVie’s MAVYRET® as First and Only 8-Week Treatment for Acute Hepatitis C in Adults and Children Aged 3 and Above AbbVie has received a significant regulatory boost for its hepatitis C treatment portfolio as the U.S.…
Ascendis Pharma Reports Promising Week 26 Results from COACH Trial: TransCon hGH Enhances TransCon CNP Benefits in Children with Achondroplasia Ascendis Pharma A/S, a global biopharmaceutical company focused on developing innovative therapies for rare diseases and endocrine disorders, has announced…
WHO Maintains Global Health Emergency Status for Mpox Amid 2024 Surge, Issues Strengthened Recommendations In response to the continuing resurgence of mpox across several regions in 2024, the World Health Organization (WHO) convened the fourth meeting of the International Health…
Jazz Pharmaceuticals Showcases Promising Phase 4 Results for Xywav® in Narcolepsy at SLEEP 2025, Underscoring Cardiovascular and Symptom Management Benefits Jazz Pharmaceuticals plc presented compelling new late-breaking data at the prestigious SLEEP 2025 conference, unveiling Phase 4 clinical results that…
Alnylam Secures European Commission Approval for AMVUTTRA® to Treat Cardiomyopathy in ATTR Amyloidosis Alnylam Pharmaceuticals, a global leader in RNA interference (RNAi) therapeutics, has received European Commission (EC) approval for an expanded indication of its RNAi drug AMVUTTRA® (vutrisiran). The…
Merck’s Pimicotinib Accepted for Priority Review in China, Offering Hope for Patients with TGCT Merck, a prominent global science and technology company, announced a significant milestone in its oncology portfolio as the Center for Drug Evaluation (CDE) under China’s National…
FDA Approves Merck’s ENFLONSIA™ to Protect Infants from Severe RSV Illness Merck operating as MSD outside the United States and Canada, has received a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) granting approval for ENFLONSIA™ (clesrovimab-cfor).…
Global Pharmaceutical Contract Sales Outsourcing Market to Reach $24.8 Billion by 2030: Strategic Insights, Regional Trends, and Technological Shifts Reshaping the Landscape The global pharmaceutical contract sales outsourcing (CSO) market is entering a transformative phase, with its value expected to…
JCR Pharmaceuticals Celebrates 50 Years of Innovation with Global Website Launch That Reflects Its Expanding Reach and Human-Centric Mission As JCR Pharmaceuticals commemorates its 50th anniversary, the global specialty biopharmaceutical company is marking this major milestone with the launch of…
Otsuka Unveils Promising Phase 3 Results for Sibeprenlimab in IgA Nephropathy, Marking Significant Proteinuria Reduction and Advancing a Novel APRIL-Targeted Therapy Otsuka Pharmaceutical Development & Commercialization, Inc., in collaboration with Otsuka Pharmaceutical Co., Ltd., has announced encouraging interim findings from…